INRLF (INRLF) Stock Price & Analysis
INRLF (INRLF) rose 2.19% to USD 2.8 as of June 10, 2026 at 03:48 UTC, according to Nexqual real-time market data.
INRLF last closed at USD 2.74; the session ranged USD 2.8–2.8 on volume of 400 shares. Market capitalization is $531.01M, with a 52-week range of USD 2.46–6.28 (PNK). Source: Nexqual, June 10, 2026 at 03:48 UTC.
Key Statistics (as of June 10, 2026 at 03:48 UTC)
| Price | USD 2.8 |
|---|---|
| Change | ▲ 2.19% (up) |
| Previous Close | USD 2.74 |
| Open | USD 2.8 |
| Day Range | USD 2.8 – 2.8 |
| 52-Week Range | USD 2.46 – 6.28 |
| Volume | 400 shares |
| Market Cap | $531.01M |
| Exchange | PNK |
Technical Analysis (INRLF)
Nexqual's technical model rates INRLF "SELL" based on 2 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 03:48 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.05 (neutral) |
| vs SMA50 | Below (USD 2.84) |
| MACD | -0.07 (negative) |
Analyst Ratings (INRLF)
Wall Street analysts rate INRLF "None", per Nexqual as of June 10, 2026 at 03:48 UTC.
| Consensus Rating | None |
|---|
Earnings (INRLF)
| Next Earnings Date | 2026-03-18 |
|---|---|
| Revenue Estimate | $37.72M |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financials & Fundamentals (INRLF)
| Total Revenue | $156.33M |
|---|---|
| Revenue Growth (YoY) | -37.20% |
| Gross Margin | -25.27% |
| Operating Margin | -76.67% |
| Profit Margin | -88.30% |
| ROE | -109.57% |
| Debt / Equity | 273.15 |
| Current Ratio | 2.14 |
| Total Cash | $105.27M |
| Total Debt | $209.50M |
| Free Cash Flow | $-31.01M |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Financial Health Score (INRLF)
Nexqual rates INRLF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:48 UTC.
| Growth | Mixed — Revenue +3.0% YoY (annual), slow |
|---|---|
| Profitability | Critical — Gross margin -25%, operating -77% |
| Balance Sheet | Weak — $105M cash vs $210M debt |
| Cash Flow | Weak — FCF negative: -$31M, burning cash |
| Efficiency | Critical — ROE -110%, ROA -14.5% |
Ownership (INRLF)
| Insider Ownership | +10.72% |
|---|---|
| Institutional Ownership | +23.19% |
| Shares Outstanding | 189.65M |
| Float | 147.38M |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Leadership (INRLF)
INRLF is led by Thomas Lingelbach (age 62), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:48 UTC.
| President, CEO & Director | Thomas Lingelbach (age 62) |
|---|---|
| Chief Financial Officer | Peter Buhler (age 54) |
| Chief Operating Officer | Vincent Dequenne (age 58) |
| Chief Scientific Officer | Hanneke Schuitemaker (age 60) |
| Vice President of Investor Relations | Joshua Drumm |
Major Backers & Investors (INRLF)
Notable institutional backers of INRLF include General American Investors Company, Inc., according to Nexqual as of June 10, 2026 at 03:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| General American Investors Company, Inc. | 0.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.24% |
| State Street | 0.18% |
Source: Nexqual, June 10, 2026 at 03:48 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VALN | Valneva SE | USD 5.31 | ▼ 3.1% |
| OXBDF | Oxford Biomedica PLC | USD 8.44 | ▲ 6.63% |
| CASBF | CANSINO BIOLOGICS INC | USD 3.97 | ▲ 28.06% |
| IDRSF | IDORSIA LTD | USD 5.75 | ▲ 0% |
| PTCHF | PureTech Health PLC | USD 1.8 | ▼ 3.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:48 UTC. This page is informational and not investment advice.